[Significance of biomarkers and surrogate endpoints in preclinical and clinical trials]
Vojnosanit Pregl
.
2007 Aug;64(8):561-7.
doi: 10.2298/vsp0708561i.
[Article in Serbian]
Authors
Katarina Ilić
1
,
Vesna Kuntić
Affiliation
1
Farmaceutski fakultet, Vojvode Stepe 450, PO BOX 146, 11 221 Beograd, Srbija. kettyilic@hotmail.com
PMID:
17874725
DOI:
10.2298/vsp0708561i
No abstract available
Publication types
Review
MeSH terms
Biomarkers*
Biomedical Research*
Clinical Trials as Topic*
Humans
Substances
Biomarkers